Skip to main content

Revolutionary vaccines to prevent pandemic and seasonal outbreaks of respiratory viral infections: The best-in-class UNIVERSAL multi-season influenza vaccine

Project description

Novel universal vaccine against seasonal flu outbreaks

Seasonal flu and other respiratory RNA viral infections affect ~10 % of the global population every year. Existing prophylactic vaccination has limited efficacy and requires updates each flu season or pandemic outbreak due to the high mutation rate of the viral surface proteins targeted by current vaccines. French clinical-stage biotech OSIVAX aims to develop novel vaccines to prevent respiratory viral infections for multiple seasons and outbreaks. OSIVAX has developed OVX836, a universal flu vaccine candidate based on a proprietary immune-boosting technology that triggers targeted and durable immune responses. OVX836 circumvents the annual vaccination updates by targeting an intraviral protein conserved across all influenza strains. The goal of the EU-funded OSIRIX project is to prepare OVX836 for the clinical proof-of-efficacy milestone.

Call for proposal

H2020-EIC-SMEInst-2018-2020-3
See other projects for this call

Funding Scheme

SME-2b - SME Instrument (grant only and blended finance)

Coordinator

OSIVAX SAS
Address
4 Rue De Copenhague
75008 Paris
France
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 2 461 122,48